Related Experiment Video

Updated: May 3, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium

Julie Ducreux1, Patrick Durez, Christine Galant

  • 1Université Catholique de Louvain, Brussels, Belgium.

Arthritis & Rheumatology (Hoboken, N.J.)
|January 23, 2014
PubMed
Abstract

Insights

Tocilizumab (TCZ) and methotrexate (MTX) treatments significantly decrease chemokine and T cell activation genes in rheumatoid arthritis (RA) synovium. These findings suggest synergistic roles for B cell and IL-6 pathways in RA pathogenesis.

Area of Science:

  • Rheumatology
  • Immunology
  • Molecular Biology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation.
  • Understanding the molecular mechanisms of RA treatment is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To compare the global molecular effects of tocilizumab (TCZ) and methotrexate (MTX) in RA synovial tissue.
  • To correlate these effects with previous data from adalimumab (ADA) and rituximab (RTX) treatments.

Main Methods:

  • Paired synovial biopsy samples from TCZ- and MTX-treated RA patients were analyzed at baseline and 12 weeks.
  • Gene expression profiling was performed using microarrays and quantitative PCR.
  • Immunohistochemistry assessed synovial cell populations and histology.

Main Results:

  • TCZ treatment significantly reduced expression of chemokine and T cell activation genes in RA synovium.
  • These molecular changes mirrored those seen with MTX and rituximab (RTX).
  • TCZ effects differed from adalimumab (ADA), which primarily impacted cell proliferation genes.

Conclusions:

  • TCZ, RTX, and MTX therapies share molecular similarities in RA synovium, highlighting synergistic roles of B cell and IL-6 pathways.
  • These pathways, particularly T cell activation, are critical in RA pathogenesis.
  • Findings support personalized therapeutic strategies based on synovial molecular profiles.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.5K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Acute Inflammation II: Local and Systemic Effects01:25

Acute Inflammation II: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
56
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K